
|Videos|September 18, 2014
Dr. Lazarus Discusses Companion Diagnostics
Author(s)Tadd Lazarus, MD
Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.
Advertisement
Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.
Diagnostics provide the foundation of care, Lazarus says, and companion diagnostics are no exception. Ten years ago, 5-10% of drugs in the pipeline had a corresponding biomarker – today, up to 45% of drugs do.
Companion diagnostics allow clinicians to select the group of patients that will most likely respond to that drug. New drugs, Lazarus says, often have a better safety profile compared with older drugs but must be used selectively due to cost and other factors.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































